36 RESULTS
COMMENT It is a pity that this compound has failed. BACE1 is currently one of the most promising AD drug targets and was also planned to be tested in the DIAN prevention trial. More BACE1 inhibitors need to be tested in the clinic—and, in fact, additional clinica
COMMENT This paper by Michael Boulton and colleagues adds a surprising and interesting twist to our understanding of the physiological function and the therapeutic potential of BACE1. The main functional findings and their implications for drug development have b
COMMENT This is the latest paper in a series of studies looking at the modifying effect of LR11/SorLA on APP processing. Despite some differences to the previous paper by Andersen and coworkers, this study clearly highlights that increases in LR11/SorLA expressio
COMMENT It is great to see the continuation of the work on sorLA. The authors previously found that this protein influences APP shedding and Aβ generation, both under overexpression and knockout conditions. Their new work sheds more light on the underlying molecu
COMMENT It has been known for a while that the ectodomain of type I membrane proteins needs to be proteolytically trimmed before the proteins can be further processed by γ-secretase. This led to the speculation that γ-secretase—and more specifically, the nicastri
COMMENT As mentioned above in the comment posted by Martin Citron (March 18, 2004), we have a paper in EMBO Reports dealing with translational control of BACE1 expression (Lammich et al., 2004). Like Mauro et al. and De Pietri Tonelli et al., we also found that t
